Alnylam Pharmaceuticals has seen its Fair Value Estimate rise from $467.94 to $480.17, reflecting a modestly stronger outlook supported by recent analyst enthusiasm. This updated assessment comes ...
Peyto Exploration & Development Corp. ("Peyto" or the "Company") is pleased to report operating and financial results for the third quarter of 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback